Mesoporous silica nanoparticles (MSNs) have shown great potential in improving drug delivery of poorly water soluble (BCS class II, IV) and poorly permeable (BCS class III, IV) drugs, as well as facilitating successful delivery of unstable compounds. The nanoparticle technology would allow improved treatment by reducing adverse reactions of currently approved drugs and possibly reintroducing previously discarded compounds from the drug development pipeline. This study aims to highlight important aspects in mesoporous silica nanoparticle (MSN) ink formulation development for digital inkjet printing technology and to advice on choosing a method (2D/3D) for nanoparticle print deposit characterization. The results show that both unfunctionalized and polyethyeleneimine (PEI) surface functionalized MSNs, as well as drug-free and drug-loaded MSN–PEI suspensions, can be successfully inkjet-printed. Furthermore, the model BCS class IV drug remained incorporated in the MSNs and the suspension remained physically stable during the processing time and steps. This proof-of-concept study suggests that inkjet printing technology would be a flexible deposition method of pharmaceutical MSN suspensions to generate patterns according to predefined designs. The concept could be utilized as a versatile drug screening platform in the future due to the possibility of accurately depositing controlled volumes of MSN suspensions on various materials.
- drug delivery
- mesoporous silica nanoparticles
- inkjet printing technology
SormenjälkiSukella tutkimusaiheisiin 'Inkjet Printing of Drug-Loaded Mesoporous Silica Nanoparticles - A Platform for Drug Development'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.
Martti Toivakka (PI), Jessica Rosenholm (PI), Nicklas Anttu (PI), Johan Bobacka (PI), Tan Phat Huynh (PI), Jouko Peltonen (PI), Xiaoju Wang (PI), Carl-Eric Wilen (PI), Chunlin Xu (PI), Hongbo Zhang (PI) & Ronald Österbacka (PI)Faculty of Science and Engineering